Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1

About this update from Telomir Pharmaceuticals, Inc.

MIAMI, FL - Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ('Telomir' or the 'Company'), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related diseases, announced the successful closing of its previously announced acquisition of TELI Pharmaceuticals, Inc. ('TELI'). The transaction, which was approved by Telomir's shareholders at the Company's Annual Meeting held on March 23, 2026, establishes Telomir as the sole holder of the global rights of Telomir-1 (Telomir-Zn), consolidating worldwide rights under a single corporate structure. Management CommentaryErez Aminov, Chief Executive Officer of Telomir, stated: 'The closing of this transaction represents a defining milestone for Telomir. By securing worldwide rights to Telomir-1 (Telomir-Zn), we have established a globally unified platform as we advance toward clinical development. Combined with our recent IND submission for Telomir-Zn, this positions the Company to progress into the clinic while maintaining the flexibility to evaluate global partnership opportunities.' The acquisition eliminates prior geographic fragmentation of the Telomir-1 (Telomir-Zn) platform and provides Telomir with full control over development and potential commercialization across major international markets. Prior to the transaction, North American and international rights were held separately. In connection with the transaction, the Company received $1.0 million in funding at closing and may receive up to an additional $4.0 million in milestone-based contributions from certain former TELI shareholders. These potential contributions are tied to key development milestones, including acceptance of an Investigational New Drug (IND) application and initiation of a Phase 1/2 clinical trial, and are subject to participation by such shareholders, aligning potential capital support with clinical advancement. Clinical Development The closing follows Telomir's recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Telomir-Zn for the treatment of advanced and metastatic triple-negative breast cancer. If the IND is cleared, the Company plans to initiate a Phase 1/2 clinical trial evaluating Telomir-Zn as an oral monotherapy in patients with advanced or metastatic triple-negative breast cancer. Transaction...

View stock analysis, news, and events for Telomir Pharmaceuticals, Inc.